India MCA Insolvency Liquidation Filings — September 24, 2026

NCLT approval of resolution plan by Advaita Trading Private Limited marks a successful CIRP exit; potential for value recovery for creditors and possible relisting/restructuring upside

Capital restructuring extinguishes all promoter/promoter group shares without payment; public shareholders face 50:1 consolidation and dilution to 5% post-issue; severe value destruction for existing shareholders

Proposed merger of 74.86%-owned subsidiary TPL Plastech into itself simplifies corporate structure; potential for cost synergies and improved consolidated margins; board meeting on Sep 29, 2026 is a key catalyst

Merger into parent Time Technoplast at a time when parent holds 74.86% stake; minority shareholders may receive fair valuation but lose listing status; watch for swap ratio details

First board meeting held post-CIRP admission (Jul 9, 2026) with appointment of new CS; early-stage CIRP suggests significant uncertainty and potential for equity wipeout

NCLT-directed shareholder meetings for merger/arrangement on Oct 24, 2026; no financial details disclosed, but merger activity signals consolidation in pharma sector

Record date for capital restructuring is Oct 1, 2026; public shareholders must act before this date to avoid severe dilution; trading likely to reflect this risk

Promoter shares extinguished without payment; public shares consolidated 50:1 and diluted to 5% post-issue; existing shareholders face near-total value loss

Company admitted to CIRP on Jul 9, 2026; first board meeting held Sep 24, 2026; no resolution plan yet, implying high risk of liquidation or severe equity dilution

Merger with parent Time Technoplast will result in delisting of TPL Plastech; minority shareholders may be forced to exit at potentially unfavorable terms

Shareholder meetings scheduled for Oct 24, 2026; any dissent or regulatory hurdles could delay or derail the merger plan

Resolution plan approved but no details on operational turnaround or financial restructuring; execution risk remains

Merger requires approvals from shareholders, stock exchanges, and NCLT; any delay or rejection could impact consolidation timeline

Post-restructuring, public shareholders hold only 5% equity, effectively losing control and influence; potential for litigation

Merger of TPL Plastech (74.86% owned) could unlock cost synergies, simplify group structure, and improve consolidated ROE; board meeting Sep 29 is near-term catalyst

NCLT-approved resolution plan by Advaita Trading could signal a fresh start; if the company relists or restructures debt, early investors may benefit from recovery

Shareholder meeting on Oct 24, 2026; if merger terms are favorable, there may be arbitrage opportunity between current price and implied merger value

For distressed debt investors, the resolution plan may offer recovery value; public equity is likely worthless but debt holders could see partial recovery

Mohd Nazim Khan as Chairman of Monitoring Committee (IBBI registered) suggests professional oversight; potential for a structured resolution plan if assets are viable

Parent company absorbing subsidiary is a positive signal of management confidence in the merged entity's prospects; watch for improved earnings visibility post-merger

Two distinct paths emerge: Zicom exits CIRP successfully (resolution plan approved), while Jatalia enters early-stage CIRP; Rajeswari undergoes capital restructuring without formal CIRP exit; investors must differentiate between recovery and wipeout scenarios

Time Technoplast and TPL Plastech propose a merger, while Venmax Drugs is also pursuing a scheme of arrangement; this indicates a trend of corporate simplification and consolidation in mid-cap Indian companies

Rajeswari's capital restructuring (promoter shares extinguished, public diluted to 5%) highlights the severe value erosion for equity holders in stressed companies; a cautionary tale for investors in distressed equities

Multiple filings have specific dates (Oct 1 record date for Rajeswari, Oct 24 shareholder meeting for Venmax, Sep 29 board meeting for Time Technoplast/TPL Plastech); these create time-bound trading and arbitrage opportunities

All 7 filings are procedural (NCLT orders, board meeting intimation) with zero financial metrics; this limits quantitative analysis but emphasizes the importance of qualitative legal and regulatory signals in insolvency monitoring

Board meeting on Sep 29, 2026 to consider merger scheme; watch for swap ratio, valuation details, and timeline for NCLT approval

Shareholder meeting on Oct 24, 2026 for merger/arrangement; monitor for any dissent or regulatory objections

Record date Oct 1, 2026 for capital restructuring; watch for trading volume and price action as public shareholders react to dilution

Post-resolution plan approval, monitor for any updates on implementation, relisting, or operational turnaround

First board meeting held Sep 24; watch for next steps in CIRP, including invitation for resolution plans or potential liquidation

Monitor for any appeals or challenges to the Zicom resolution plan or Rajeswari restructuring, which could impact timelines

Watch for any new CIRP admissions in the pharmaceutical (Venmax) or packaging (TPL/Time Technoplast) sectors, which could signal broader stress